These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22708140)

  • 1. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 2. OVERDOSED ON OPIOIDS: A deadly opioid epidemic sweeping the country has lawmakers working hard to find solutions.
    Hoback J
    State Legis; 2016 Apr; 42(4):9-13. PubMed ID: 27071212
    [No Abstract]   [Full Text] [Related]  

  • 3. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
    Bachireddy C; Weisberg DF; Altice FL
    Addiction; 2015 Dec; 110(12):1869-71. PubMed ID: 26464200
    [No Abstract]   [Full Text] [Related]  

  • 6. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
    Vidyasagar N; Bunting SR; Arora VM; Ari M
    JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
    Cooper HLF; Cloud DH; Young AM; Freeman PR
    N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
    [No Abstract]   [Full Text] [Related]  

  • 8. Painkiller crackdown.
    Kalb C
    Newsweek; 2001 May; 137(20):38. PubMed ID: 11373803
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment options for opiate addiction.
    J Ky Med Assoc; 2004 May; 102(5):221-4. PubMed ID: 15152448
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?
    Costa E Silva JA
    Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
    Katz MH; Kotabe S
    Med Care; 2008 Sep; 46(9):1002. PubMed ID: 18725857
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription pain medication dependence.
    Dodrill CL; Helmer DA; Kosten TR
    Am J Psychiatry; 2011 May; 168(5):466-71. PubMed ID: 21536702
    [No Abstract]   [Full Text] [Related]  

  • 18. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
    Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OxyContin: maintaining availability and efficacy while preventing diversion and abuse.
    Regan JJ; Alderson A
    Tenn Med; 2003 Feb; 96(2):88-90. PubMed ID: 12645369
    [No Abstract]   [Full Text] [Related]  

  • 20. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.